Immunotherapy versus lenvatinib in hepatocellular carcinoma: the need for granular data and prospective validation

Immunotherapy versus lenvatinib in hepatocellular carcinoma: the need for granular data and prospective validation

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, with systemic therapies constituting the cornerstone of treatment for advanced-stage disease. While lenvatinib has been a widely used first-line agent, the advent of immunotherapy—particularly combinations...

Full description

Saved in:
Bibliographic Details
Main Authors: Ming Zhao, Song Chen, Qi-Feng Chen, Xiong-Ying Jiang
Format: Article
Language:English
Published: BMJ Publishing Group 2025-08-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/8/e012560.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items